Innovent Biologics, Inc. (FRA:6IB)

Germany flag Germany · Delayed Price · Currency is EUR
10.20
+0.20 (2.00%)
Last updated: Dec 4, 2025, 3:29 PM CET
121.74%
Market Cap 17.41B
Revenue (ttm) 1.36B
Net Income (ttm) 134.59M
Shares Out n/a
EPS (ttm) 0.08
PE Ratio 129.36
Forward PE 59.64
Dividend n/a
Ex-Dividend Date n/a
Volume 15
Average Volume 642
Open 10.20
Previous Close 10.00
Day's Range 10.20 - 10.20
52-Week Range 3.64 - 11.70
Beta n/a
RSI 52.62
Earnings Date Nov 27, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 5,659
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6IB
Full Company Profile

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.